Articles - Page 89 of 96 - Drugs in Context

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond

Lalita Prasad-Reddy, Diana Isaacs

Article Type

Review

Published

08 Jul 2015

Many of the agents used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight gain. Glucagon-like peptide-1 (GLP-1) receptor agonists represent a unique approach to the treatment of diabetes. In this article the authors discuss the various GLP-1 receptor agonists available on the market, specifically focusing on their relative efficacy, safety, and clinical differences as well as their potential benefits in addition to glucose lowering in type 2 diabetes, and describe the adverse effects and toxicities seen with these agents.

Diagnosis and management of lentigo maligna: a review

Julia M Kasprzak, Yaohul G Xu

Article Type

Review

Published

29 May 2015

In lentigo maligna, the ill-defined nature and potentially large size of lesions can pose significant diagnostic and treatment challenges. The goal of therapy is to cure the lesions in order to prevent development of invasive disease. In this article the authors describe techniques for surgical excision, which is currently the treatment of choice to achieve clear histological margins, and review the evidence for nonsurgical treatment modalities.

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder

James M Martinez, Margaret B Ferguson, Beth A Pangallo, Tina M Oakes, JonDavid Sparks, Mary Anne Dellva, Qi Zhang, Peng Liu, Mark Bangs, Jonna Ahl, Celine Goldberger

Article Type

Original Research

Published

13 May 2015

This analysis confirms that the tolerability and safety profile of edivoxetine as adjunctive treatment to SSRI antidepressants was consistent with its norepinephrine reuptake inhibitor mechanism of action, and was comparable with edivoxetine monotherapy treatment in patients with major depressive disorder.

Review of the experiences from the first childhood influenza vaccination programme with a live attenuated influenza vaccine in England and Scotland

George Kassianos, Sharon White, Arlene J Reynolds, Sankarasubramanian Rajaram

Article Type

Case Report

Published

01 May 2015

In 2012, the Joint Committee on Vaccination and Immunisation recommended that the UK National Immunisation Programme for influenza be extended to include healthy children/adolescents aged 2–17 years. The extension of this new immunisation programme began in 2013–2014 and targeted children aged 2–3 years in primary care. This article describes the processes utilised in England and Scotland for programme setup, workforce management, identification and care of contraindicated patients, collection of data on vaccine uptake, communication strategies, and education of parents and children. In light of the lessons learnt from these pilot programmes, the authors make recommendations and offer practical advice to help ensure effective preparation and management of new childhood influenza vaccination programmes in other countries.

Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease

Christopher M Blanchette, Caihua Liang, Deborah P Lubeck, Britt Newsome, Sandro Rossetti, Xiangmei Gu, Benjamin Gutierrez, Nancy D Lin

Article Type

Original Research

Published

17 Apr 2015

Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic disorder characterized by the development of numerous kidney cysts that result in kidney failure. The results of this study suggest that distribution of patients by age at transition to next stage may be useful for identification of ADPKD patients at risk of rapid progression.